These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36714265)
21. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
22. The relationship between CD34+ stem cell dose and time to neutrophil recovery in autologous haematopoietic stem cell recipients-A single centre experience. Nath K; Boles R; McCutchan A; Vangaveti V; Birchley A; Irving I Transfus Apher Sci; 2018 Aug; 57(4):532-536. PubMed ID: 29933906 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of plerixafor in pediatric cancer patients undergoing peripheral blood stem cell harvest for autologous hematopoietic stem cell transplant. Gupta AK; Meena JP; Pandey HC; Coshic P; Seth R Blood Cell Ther; 2023 Aug; 6(3):72-76. PubMed ID: 38146356 [TBL] [Abstract][Full Text] [Related]
24. Benefits of Pre-harvest Peripheral Blood CD34 Counts Guided Single Dose Therapy with PLERIXAFOR in Autologous Hematopoietic Stem Cell Transplantation: A Retrospective Study at a Tertiary Care Institute in India. Agarwal P; Tejwani N; Pathak A; Kumar D; Agrawal N; Mehta A Indian J Hematol Blood Transfus; 2019 Jan; 35(1):72-76. PubMed ID: 30828151 [TBL] [Abstract][Full Text] [Related]
25. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
26. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Singh AD; Parmar S; Patel K; Shah S; Shore T; Gergis U; Mayer S; Phillips A; Hsu JM; Niesvizky R; Mark TM; Pearse R; Rossi A; van Besien K Biol Blood Marrow Transplant; 2018 Feb; 24(2):288-293. PubMed ID: 29061534 [TBL] [Abstract][Full Text] [Related]
32. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983 [TBL] [Abstract][Full Text] [Related]
33. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient. Prakash VS; Malik PS; Sahoo RK; Pramanik R; Choudhary P; Varshney AN; Kumar L Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):44-51. PubMed ID: 34452863 [TBL] [Abstract][Full Text] [Related]
34. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC; Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586 [TBL] [Abstract][Full Text] [Related]
35. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma. Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522 [TBL] [Abstract][Full Text] [Related]
36. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Gunn N; Damon L; Varosy P; Navarro W; Martin T; Ries C; Linker C Biol Blood Marrow Transplant; 2003 Oct; 9(10):643-8. PubMed ID: 14569560 [TBL] [Abstract][Full Text] [Related]
37. Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre. Bai L; Xia W; Wong K; Reid C; Ward C; Greenwood M Ann Hematol; 2014 Oct; 93(10):1655-64. PubMed ID: 24870941 [TBL] [Abstract][Full Text] [Related]
38. Flat-dose granulocyte colony-stimulating factor evaluation after autologous hematopoietic stem cell transplant in multiple myeloma patients: Does one dose fit all? Kim OM; Jared JR; Hennes ER; Ninos CL; Przybylski DJ; Callander NS J Oncol Pharm Pract; 2021 Oct; 27(7):1716-1722. PubMed ID: 33100179 [TBL] [Abstract][Full Text] [Related]
39. Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature. Tiwari AK; Arora D; Dara RC; Dorwal P; Sood N; Misra R; Gupta SK; Raina V; Vaid AK Indian J Med Paediatr Oncol; 2016; 37(3):168-73. PubMed ID: 27688610 [TBL] [Abstract][Full Text] [Related]
40. Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation. D'Rozario J; Parisotto R; Stapleton J; Gidley A; Owen D Transfus Apher Sci; 2014 Jun; 50(3):443-50. PubMed ID: 24680293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]